XTL Biopharmaceuticals
1.25
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About XTL Biopharmaceuticals
XTL Biopharmaceuticals Ltd., empresa biofarmacéutica, se dedica a la adquisición y desarrollo de productos farmacéuticos para el tratamiento de enfermedades autoinmunes. Su principal candidato a fármaco es hCDR1, un activo listo para la fase II para el tratamiento del lupus eritematoso sistémico y el síndrome de Sjogren. XTL Biopharmaceuticals Ltd. tiene un acuerdo de licencia con Yeda Research and Development Company Limited para la investigación, desarrollo y comercialización de hCDR1 para diversas indicaciones. La empresa era conocida anteriormente como Xenograft Technologies Ltd. y cambió su nombre por el de XTL Biopharmaceuticals Ltd. en julio de 1995. XTL Biopharmaceuticals Ltd. se fundó en 1993 y tiene su sede en Ramat Gan, Israel.
Trade GPT
Similar Stocks
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.